Last reviewed 2026-04-20 · How we verify

Denosin® and Xyzal®

Lotus Pharmaceutical · FDA-approved active Small molecule Quality 2/100

Denosin® and Xyzal® is a Small molecule drug developed by Lotus Pharmaceutical. It is currently FDA-approved.

At a glance

Generic name	Denosin® and Xyzal®
Sponsor	Lotus Pharmaceutical
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Denosin® and Xyzal® CI brief — competitive landscape report
Denosin® and Xyzal® updates RSS · CI watch RSS
Lotus Pharmaceutical portfolio CI

Frequently asked questions about Denosin® and Xyzal®

What is Denosin® and Xyzal®?

Denosin® and Xyzal® is a Small molecule drug developed by Lotus Pharmaceutical.

Who makes Denosin® and Xyzal®?

Denosin® and Xyzal® is developed and marketed by Lotus Pharmaceutical (see full Lotus Pharmaceutical pipeline at /company/lotus-pharmaceutical).

What development phase is Denosin® and Xyzal® in?

Denosin® and Xyzal® is FDA-approved (marketed).

Manufacturer: Lotus Pharmaceutical — full pipeline
Compare: Denosin® and Xyzal® vs similar drugs
Pricing: Denosin® and Xyzal® cost, discount & access